Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BDSX

BDSX - Biodesix Inc Stock Price, Fair Value and News

$17.99-1.16 (-6.06%)
Market Closed

64/100

BDSX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

64/100

BDSX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BDSX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BDSX Price Action

Last 7 days

-4.2%

Last 30 days

73.8%

Last 90 days

129.2%

Trailing 12 Months

21.1%

BDSX RSI Chart

BDSX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BDSX Valuation

Market Cap

177.4M

Price/Earnings (Trailing)

-5.03

Price/Sales (Trailing)

2

Price/Free Cashflow

-7.54

BDSX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BDSX Fundamentals

BDSX Revenue

Revenue (TTM)

88.5M

Rev. Growth (Yr)

40.76%

Rev. Growth (Qtr)

32.1%

BDSX Earnings

Earnings (TTM)

-35.3M

Earnings Growth (Yr)

51.76%

Earnings Growth (Qtr)

54.34%

BDSX Profitability

Return on Equity

1.4K%

Return on Assets

-40.31%

Free Cashflow Yield

-13.27%

BDSX Investor Care

Shares Dilution (1Y)

35.07%

Diluted EPS (TTM)

-4.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202574.5M76.6M80.2M88.5M
202454.8M60.9M65.6M71.3M
202340.7M41.6M44.0M49.1M
202232.2M31.3M35.8M38.2M
202169.3M77.0M74.3M54.5M
202029.8M35.1M40.3M45.6M
201900024.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Biodesix Inc

BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
 CEO
 WEBSITEbiodesix.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES245

Biodesix Inc Frequently Asked Questions

BDSX is the stock ticker symbol of Biodesix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Biodesix Inc is 177.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, BDSX's PE ratio (Price to Earnings) is -5.03 and Price to Sales (PS) ratio is 2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDSX PE ratio will change depending on the future growth rate expectations of investors.